已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Efficacy of anti‐IL‐23 and anti‐IL‐17 after adalimumab failure in psoriatic patients

阿达木单抗 医学 银屑病性关节炎 银屑病 内科学 白细胞介素17 白细胞介素23 胃肠病学 肿瘤坏死因子α 免疫学 细胞因子
作者
Luca Mastorino,Sara Susca,Caterina Cariti,Niccolò Sliquini,Anna Verrone,Elena Stroppiana,M. Ortoncelli,Paolo Dapavo,Simone Ribero,Pietro Quaglino
出处
期刊:Journal of The European Academy of Dermatology and Venereology [Wiley]
卷期号:37 (9): 1848-1853 被引量:16
标识
DOI:10.1111/jdv.19135
摘要

Many national guidelines at the European level recommend first-line therapy based on the anti-TNF-alpha adalimumab for treatment of psoriasis and psoriatic arthritis, mainly for economic reasons. Consequently, patients being treated with newer IL-17 and IL-23 inhibitors underwent previous unsuccessful first-line adalimumab-based therapy.Evaluate the efficacy and safety of IL-17 and IL-23 inhibitors after treatment with adalimumab compared to adalimumab-naive psoriatic patients.We retrospectively analysed 1053 psoriatic patients treated with anti-IL17 and anti-IL23 agents, which included 68 and 24 adalimumab-experienced and 399 and 260 bio-naive patients. Efficacy was assessed with mean PASI, PASI90, PASI100, and <3.Concerning the achieving of PASI100, PASI90 and PASI < 3 in patients treated with anti-IL17 agents, no significant differences were observed between adalimumab-experienced and bio-naive patients. In patients treated with an anti-IL-23 agent, a faster response was observed in bio-naive patients, with PASI < 3 significantly higher than ADA-experienced patients at 16 weeks (77% vs. 58% p = 0.048). In a sub-analysis that evaluated the performance of anti-IL17 and anti-IL23 agents in adalimumab-experienced patients with a history of secondary failure, no significant differences were found. In multivariate analysis of PASI100, only anti-IL-17 therapy appeared to have a negative impact at 52 weeks (OR: 0.54 p = 0.04) independently of previous treatment. For PASI90, type of treatment and bio-naïve status did not seem to have an impact at any time point.Anti-IL 23 and anti-IL 17 agents are not significantly different in terms of efficacy in bio-naive patients or as second-line therapy after failure with a biosimilar or originator adalimumab.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
nihao完成签到 ,获得积分10
2秒前
晶晶发布了新的文献求助10
3秒前
小燕子发布了新的文献求助10
5秒前
5秒前
大学生发布了新的文献求助10
6秒前
浮生若梦发布了新的文献求助10
8秒前
谨慎雪碧发布了新的文献求助10
8秒前
慎默应助酷炫的冰淇淋采纳,获得10
10秒前
Anthonywll完成签到 ,获得积分10
12秒前
Nicole完成签到 ,获得积分10
15秒前
16秒前
直觉发布了新的文献求助10
21秒前
24秒前
24秒前
领导范儿应助桀桀桀采纳,获得10
24秒前
25秒前
26秒前
小燕子完成签到,获得积分10
28秒前
loong发布了新的文献求助10
30秒前
hhllhh发布了新的文献求助10
30秒前
畅快芾发布了新的文献求助30
31秒前
安生完成签到,获得积分10
31秒前
周思齐完成签到 ,获得积分20
32秒前
如果发布了新的文献求助10
33秒前
CodeCraft应助loong采纳,获得10
35秒前
FashionBoy应助七爷采纳,获得10
36秒前
浮生若梦完成签到,获得积分10
38秒前
粒er完成签到 ,获得积分10
38秒前
科研通AI2S应助zhao采纳,获得10
39秒前
omgggg完成签到,获得积分10
40秒前
44秒前
丘比特应助虚影采纳,获得10
51秒前
头发茂密的我完成签到,获得积分10
51秒前
51秒前
51秒前
桀桀桀发布了新的文献求助10
55秒前
55秒前
赘婿应助Arui采纳,获得10
56秒前
59秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
Aktuelle Entwicklungen in der linguistischen Forschung 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989868
求助须知:如何正确求助?哪些是违规求助? 3531994
关于积分的说明 11255752
捐赠科研通 3270793
什么是DOI,文献DOI怎么找? 1805053
邀请新用户注册赠送积分活动 882215
科研通“疑难数据库(出版商)”最低求助积分说明 809208